LENZ Therapeutics (LENZ) Research & Development (2020 - 2025)
LENZ Therapeutics (LENZ) reported Research & Development of $3.8 million for Q3 2025, down 41.23% year-over-year from $6.5 million in Q3 2024, and down 58.16% on a QoQ basis from $9.1 million in Q2 2025.
LENZ Therapeutics (LENZ) has 6 years of Research & Development data on file, last reported at $3.8 million in Q3 2025.
- Quarterly Research & Development fell 41.23% year-over-year to $3.8 million in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $12.9 million (down 48.76% YoY) and the FY2025 annual result came in at $18.7 million, down 37.35% from the prior year.
- Research & Development fell to $3.8 million in Q3 2025 per LENZ's latest filing, from $9.1 million in the prior quarter.
- Across five years, Research & Development topped out at $19.5 million in Q4 2023 and bottomed at $3.8 million in Q3 2025.
- The 5-year median for Research & Development is $10.5 million (2024), against an average of $11.5 million.
- The widest annual swing landed in 2021, when Research & Development soared 16623.88%; it then tumbled 69.96% in 2024.
- Tracing LENZ's Research & Development over 5 years: stood at $11.2 million in 2021, then soared by 64.77% to $18.5 million in 2022, then increased by 5.82% to $19.5 million in 2023, then plunged by 69.96% to $5.9 million in 2024, then plunged by 35.4% to $3.8 million in 2025.
- Per Business Quant, the three latest LENZ Research & Development figures stand at $3.8 million (Q3 2025), $9.1 million (Q2 2025), and $5.8 million (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3.79 Mn |
| Jun 30, 2025 | 9.06 Mn |
| Mar 31, 2025 | 5.82 Mn |
| Dec 31, 2024 | 5.87 Mn |
| Sep 30, 2024 | 6.45 Mn |
| Jun 30, 2024 | 6.95 Mn |
| Mar 31, 2024 | 10.54 Mn |
| Dec 31, 2023 | 19.54 Mn |
| Sep 30, 2023 | 17.00 Mn |
| Jun 30, 2023 | 12.64 Mn |
| Mar 31, 2023 | 10.33 Mn |
| Dec 31, 2022 | 18.46 Mn |
| Sep 30, 2022 | 18.30 Mn |
| Jun 30, 2022 | 17.78 Mn |
| Mar 31, 2022 | 18.25 Mn |
| Dec 31, 2021 | 11.21 Mn |
| Sep 30, 2021 | 8.68 Mn |
| Jun 30, 2021 | 12.67 Mn |
| Mar 31, 2021 | 5.38 Mn |
| Dec 31, 2020 | 67,000.00 |
| Sep 30, 2020 | 2.31 Mn |
| Jun 30, 2020 | 423,000.00 |